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Background: Advances in DNA sequencing and proteomics have facilitated quantitative comparisons of snake
venom composition. Most studies have employed one approach or the other. Here, both Illumina cDNA
sequencing and LC/MS were used to compare the transcriptomes and proteomes of two pit vipers, Protobothrops
flavoviridis and Ovophis okinavensis, which differ greatly in their biology.
Results: Sequencing of venom gland cDNA produced 104,830 transcripts. The Protobothrops transcriptome contained
transcripts for 103 venom-related proteins, while the Ovophis transcriptome contained 95. In both, transcript abundances
spanned six orders of magnitude. Mass spectrometry identified peptides from 100% of transcripts that occurred at higher
than contaminant (e.g. human keratin) levels, including a number of proteins never before sequenced from snakes. These
transcriptomes reveal fundamentally different envenomation strategies. Adult Protobothrops venom promotes
hemorrhage, hypotension, incoagulable blood, and prey digestion, consistent with mammalian predation. Ovophis
venom composition is less readily interpreted, owing to insufficient pharmacological data for venom serine and
metalloproteases, which comprise more than 97.3% of Ovophis transcripts, but only 38.0% of Protobothrops transcripts.
Ovophis venom apparently represents a hybrid strategy optimized for frogs and small mammals.
Conclusions: This study illustrates the power of cDNA sequencing combined with MS profiling. The former quantifies
transcript composition, allowing detection of novel proteins, but cannot indicate which proteins are actually secreted,
as does MS. We show, for the first time, that transcript and peptide abundances are correlated. This means that MS can
be used for quantitative, non-invasive venom profiling, which will be beneficial for studies of endangered species.
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Toxins, EnzymesBackground
Snakes employ a great variety of biochemical compounds
to immobilize, kill, and digest their prey [1,2], although
whether venom actually augments assimilation efficiency
is a matter of continuing debate [2-6]. Biochemical mech-
anisms employed in prey envenomation involve a complex
interplay between venom chemistry and homeostatic
mechanisms in the prey; thus, envenomation success
depends upon exploiting the prey’s biochemistry [1].
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reproduction in any medium, provided the orof the snake and the nature of its principal prey, factors
that change ontogenetically and geographically [7-13].
Biochemical components of a venom participate in one
or more of three fundamental envenomation strategies.
Two of these are prey immobilization strategies and may
be denominated “hypotensive” and “paralytic” strategies
[1]. Both serve to limit prey flight, in snake taxa which
strike, release, and then track their prey (most viperids),
or to overcome prey resistance, in snakes that seize and
bulldog their prey (many elapids and all colubrids). The
third strategy is digestive and commences degradation of
prey tissues internally, even before the prey has been
engulfed. Normally, all three strategies operate simultan-
eously and many individual venom components participate
in more than one of them. Each of these three strategies. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ferent venomous taxa employ different combinations of
constituents, and no single species employs them all [1].
Snake venom composition can be studied either at the
proteomic or the transcriptomic level. Traditionally, snake
proteins were sequenced after chromatographic purifica-
tion, after isolation on polyacrylamide gels, or after cloning
cDNA from the venom glands. Although these approaches
are typically necessary for studies of protein function, they
are laborious, and they are less quantitative than might
be desired. Because a relatively small number of individual
proteins or clones can be processed at one time, and
because techniques vary between labs, comparative analyses
of venom chemistry have been difficult [14,15]. Wagstaff
et al. [16] found 80% of Echis ocellatus venom proteins
identified with mass spectrometry in the corresponding
transcriptome, but 67% of transcripts were not found in the
proteome. In a study of Bothropoides pauloensis venom,
Rodrigues et al. [17] reported “a low degree of correspond-
ence” between transcriptome and proteome. The degree
of correspondence varied, depending upon the protein
family. Transcriptome and proteome were in good agree-
ment in regard to bradykinin-potentiating peptides, phos-
pholipases A2, and L-amino acid oxidase, but diverged
sharply with regard to metalloproteases and C-type lectin-
like components. To date, no study has attempted to
perform a rigorous statistical comparison of transcriptome
and proteome.
Recent technological advances in mass spectrometry
and next generation sequencing have greatly simplified both
proteomic and transcriptomic studies of snake venoms.
Snake venom transcriptomes are now routinely sequenced
on a variety of platforms, allowing examination of many
more components than has been possible traditionally. In
particular, Illumina sequencing, has allowed more accurate
quantification of mRNA composition. However, in addition
to venom proteins, next generation cDNA sequencing also
detects many non-venom components, and erroneous
assemblies are another possible source of error. The advent
of LC/MS-based venom proteomics permits high through-
put screening of venom components [18]. This approach
relies on existing databases of protein sequences, and can
be limited by the availability of reference data. LC/MS is
not typically used to estimate protein abundance. Used
together, next generation cDNA sequencing and LC/MS
have considerable power, since mass spectrometry can
validate cDNA sequencing. However, relatively few venom
studies have combined the two tools [14,16,19]. Here both
techniques were used to explore the venoms of two
Okinawan pit vipers, with the goal of understanding their
venom chemistry, and evaluating the performance of LC/
MS as a tool for quantifying venom protein composition.
Okinawa, Japan has two native pit vipers, the Okinawa
habu (Protobothrops flavoviridis) and the himehabu (Ovophisokinavensis). Human activities have introduced the
Taiwanese habu (Protobothrops mucrosquamatus) and the
Sakishima habu (Protobothrops elegans) as well. The two
native species differ in nearly all aspects of their biology.
The Okinawa habu is semi-arboreal and can reach lengths
of 2.5 m. It is active in the warmer months of the year.
In contrast, the himehabu is terrestrial, usually not
exceeding 70 cm [20] and is active at temperatures as low
as 10°C [20,21].
Most vipers and pit vipers display a well-documented
ontogenetic shift from ectothermic prey (primarily lizards
and frogs) to endotherms [22-29]. Protobothrops flavoviridis
follows the usual pattern. Nishimura et al. [30] have
documented pronounced ontogenetic dietary shifts in
Protobothrops. Okinawa habus less than 30 cm in length
feed heavily on lizards (36.3% of food items). Amphibians
comprise only 3% of the juvenile diet, while house mice
(Mus) and Horsfield’s shrews (Crocidura horsfieldi) consti-
tute another 60.6%. Subadult and adult Okinawa habus
(50-90 cm) feed less on amphibians (0.9%) and lizards
(2.4%), while birds become an important component
(7.9%), and mammals (mice, Horsfield’s and Asian house
shrews, and rats) become more important (91.7%). Habus
above 1.3 m become exclusive mammal feeders [30].
Ovophis okinavensis, by virtue of its small adult size, does
not exhibit an apparent dietary shift [20]. While it is
technically a dietary generalist [20], its seasonal activity is
strongly correlated with frog abundance. In many Ovophis
populations, frogs comprise nearly 90% of the food items
taken by both juveniles and adults [20,21].
The present study employed Illumina cDNA sequencing
and LC/MS to investigate the transcriptomes and pro-
teomes of these two native pit vipers. This was done to fur-
ther illuminate the composition of these two venoms and
to ascertain whether the two techniques were congruent.
Results and discussion
Transcriptome sequencing, assembly and mapping
After quality filtering, 13,572,340 and 12,184,487 paired-
end reads remained, as well as 2,079,603 and 3,110,164
single-end reads, in the Ovophis and Protobothrops libraries,
respectively, which were used for the assembly. When
re-mapped to the assembly using RSEM, which used only
paired-end read data, 90.4% and 92.0% of the reads were
mapped, with 73.4% and 86.7% of these reads being
properly paired in alignment. After filtering low-frequency
transcripts (less than 1 FPKM), assemblies were reduced
from 46,631 and 58,199 transcripts for Ovophis and
Protobothrops, respectively, to 13,998 and 19,970 transcripts.
Transcriptomes
The Protobothrops transcriptome contained partial and
complete transcripts for 85 identifiable toxins, representing
21 protein families (Additional file 1: Tables S1 and
Figure 1 Abundance of cDNA transcripts in venom glands of
Protobothrops flavoviridis and Ovophis okinavensis, as a percentage
of the respective transcriptomes. Abundant transcripts mask the
presence of most venom constituents, some of which are six orders of
magnitude (106-fold) less abundant. For the sake of legibility, only toxins
comprising ≥1% of either transcriptome are shown here. Toxin class
abbreviations are as follows: CRISP, cysteine-rich secretory proteins; CTL,
C-type lectin-like proteins; CTL F IX/X, C-type lectin-like activators
of Coagulation Factors IX/X; LAO, L-amino acid oxidase; MP,
metalloproteases; NGF, nerve growth factor; PLA2, phospholipase A2; and
SP, serine proteases. These two venoms are starkly different in composition.
Protobothrops venom comprises modest titers of eight toxin families,
while Ovophis venom consists overwhelmingly of SPs (93.1%) with a
lesser quantity of MPs (4.2%). Both venoms contained arrays of lesser
constituents, which also varied dramatically between the two species.
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nearly six orders of magnitude. In addition, we identified
another 18 sequences in nine more families that are either
known to contribute to venom function (e.g. glutaminyl
cyclase (QC)), or which potentially do so. The latter group
includes tissue enzymes that have been recruited into some
venomes (e.g. paraoxonase) and purine and pyrimidine
biosynthetic enzymes (e.g. adenylosuccinate synthase)
that are extremely important in viperid and elapid venoms,
but less so in those of crotalids [31]. While 16 families
were represented by a single sequence (Additional file 1:
Table S1), others displayed anywhere from 2-21 sequences.
Metalloproteases (MPs) (21), serine proteases (SPs) (16),
and C-type lectins (CTLs) (12) were the most diversified
families in Protobothrops venom (Additional file 1: Table S1);
however, the most diversified families are not necessarily
the most heavily expressed. Forty of the 103 sequences were
identical or nearly so, to sequences previously published for
this species. Another 51 were most similar to toxins known
from other venomous snake taxa. The remaining 12 were
most similar to sequences from other vertebrate taxa,
including amphibians, lizards, and mammals; thus, in total
there were an estimated 63 new sequences for this species,
including the 12 that were novel for snakes.
The Ovophis transcriptome contained 76 transcripts for
identifiable toxins belonging to 19 toxin families (Additional
file 3: Tables S2 and Additional file 4: Table S5). Purine and
pyrimidine biosynthetic enzymes, acetylcholinesterase, and
glutaminyl cyclase comprised another 20 transcripts.
The range of expression levels was similar to that seen in
the Protobothrops transcriptome. In the Ovophis transcrip-
tome, SPs were the most diversified family (26 sequences),
followed by MPs (10), and CTLs (8). Only one sequence, a
phospholipase A2, has been previously published for this
species. Another 81 sequences were most similar to those
of other snakes, while 13 were most similar to sequences
from the iguanid lizard, Anolis carolinensis. In total, 94
partial and complete sequences reported herein appear to
be new for Ovophis okinavensis.
The two transcriptomes revealed fundamentally different
envenomation strategies (Figure 1; Additional file 5:
Table S3). In Protobothrops venom glands, phospholipases
A2 (PLA2) (32.1% of all transcripts) and metalloproteases
(27.0%) were the dominant constituents, followed by
Factor IX/X activators (11.6%), SP transcripts (11.1%),
and L-amino acid oxidase (LAO) (9.1%) (Additional file 1:
Table S1 and Additional file 5: Table S3; Figure 1). Thus,
these five protein classes accounted for 90.9% of all tran-
scripts. In Ovophis venom glands, SPs were the dominant
component (93.1%), followed by MPs (4.2%), PLA2 (0.65%),
LAO (0.62%), and C-type lectin-like proteins (CTL)
(0.47%), (Additional file 3: Table S2 and Additional file 5:
Table S3; Figure 1). Thus, in Ovophis, the dominant five
classes comprise 99.0% of total venom transcripts.Significant differences are also evident in terms of minor
components (Additional file 5: Tables S3, Additional file 2:
Table S4 and Additional file 4: Table S5). Three-finger
toxins (3FTx), paraoxonase, vespryn, and waprin transcripts
were found in the Protobothrops transcriptome, but were
absent in Ovophis. Five acetylcholinesterase (AChE) tran-
scripts and crotasin-like transcripts were found in the
Ovophis transcriptome, but not in that of Protobothrops.
Glutaminyl cyclase (QC) cDNA was detected at lower
levels in the Ovophis transcriptome. 5’-nucleotidase, CRISP,
CTL, nerve growth factor (NGF), and phosphodiesterase
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Protobothrops venom, whereas dipeptidyl peptidase IV
(DPP IV) was more abundant in Ovophis venom glands
(Additional file 5: Table S3).
Both transcriptomes also contained numerous transcripts
that appear unrelated to envenomation (Additional file 6:
Table S6 and Additional file 7: Table S7). The majority of
these appear to be cellular proteins and were transcribed
at very low levels. Peptides were also isolated for many of
these (Additional file 6: Table S6 and Additional file 7:
Table S7). Whether such constituents make a significant
contribution to envenomation is unknown, but it seems
unlikely.
Proteomes
Peptides were isolated from 100% of venom or venom-
related transcripts that were more abundant than contam-
inants (e.g. human keratin) (Additional file 1: Table S1 and
Additional file 3: Table S2). Peptides were also isolated
from at least 18 transcripts in the two transcriptomes that
occurred below contaminant levels (Additional file 2:
Table S4 and Additional file 4: Table S5).
Comparison between proteomic and transcriptomic
data sets
Although one would expect to find strong correlations
between venom gland mRNA and protein profiles, such
a link has been elusive [32]. Lack of correlation between
the two types of data may be due to biological reasons, such
as biased processing of messenger transcripts. Alternatively,
purely technical reasons may have prevented accurate
estimation of cDNA or protein abundance, particularly in
early studies in which sequencing by the Sanger method
limited the number of clones. Although our measure of
protein abundance was relatively crude, we were nonethe-
less able to detect a correlation (Protobothrops flavoviridis
r = 0.77, p < 2.2e-16; Ovophis okinavensis r = 0.70, p < 1.1e-12)
between mRNA and venom protein levels (Figure 2).
We were able to confirm the correlation between prote-
omic and transcriptomic estimates of protein abundance
using publicly available data from NCBI (Additional file 8:
Figure S1). There were no proteins detected in the NCBI
data set that were missing from our transcriptome, suggest-
ing that we were able to capture all of the transcriptional
diversity. The robustness of the result also argues against a
spurious correlation driven by poor assembly and mapping
of low FPKM transcripts.
The correlation, although significant, explained only
about half of the variance in the data. Apparent differences
between mRNA and protein levels may stem from several
factors, both biological and analytical. For example,
although tissue and venom samples were taken from the
same individuals, they were taken at different times. If
venom components are synthesized at different rates thetwo measurements might not agree. Likewise, it is possible
that due to extensive post-translational modification of
many venom components, not all messenger transcripts
have an equal chance of becoming mature proteins. It is
also likely that our measure of protein abundance is not
sufficiently precise, due perhaps to biased cleavage of
proteins or biases in ion detection during LC/MS. Proteins
differ in their susceptibility to enzymatic digestion. Even
though three proteases (chymotrypsin, Glu-C, and trypsin)
were used, few proteins were digested equally well by all
three. More abundant peptides are much more likely to be
detected by mass spectrometry than others. Lastly, it is
probable that incomplete transcripts stemming from the
short read length diminished the strength of the correla-
tions. Newer Illumina sequencer models (e.g., MiSeq) now
boast read lengths as great as 500 bp, which may mitigate
this problem in future studies.
There are a large number of toxin and potential toxin
transcripts that are expressed at near-zero levels (Additional
file 1: Table S1, Additional file 2: Table S4, Additional file 3:
Table S2, Additional file 4: S5, Additional file 5: Table S3).
These include 3-finger toxins, AChE, acid phosphomono-
esterase, crotasin-like proteins, paraoxonase, tissue factor
pathway inhibitor (TFPI), vespryns, waprins, and many
MP and SP transcripts. There is no evidence that many of
these are actually translated, or, if they are, they are not a
substantial proportion of the proteome. This raises the
question of what function these transcripts may now
have, or may have had previously. Are these merely tissue
transcripts that have not actually been incorporated into
the venome? How high an expression level would be re-
quired before novel venom proteins would have selective
value, or would be under selective pressure? Undoubtedly
selective pressure would vary with the biochemical en-
venomation strategy employed by the taxon in question,
and also upon the nature of the contribution made by a
given toxin to that strategy. Given the massive overkill
that most venoms generate, it is likely that a substantial
contribution would be required to generate much selective
pressure. It also seems likely that there would be more
selective pressure to increase prey immobilization efficiency
than acute toxicity or assimilation efficiency.
Major venom constituents
Metalloproteases
Snake venom MPs are presently classified into four groups,
according to domain structure and size: P-I MPs possess a
metalloprotease domain only and are largely hemorrhagic;
P-II MPs are larger, with metalloprotease and disintegrin
domains; P-III enzymes have metalloprotease, disintegrin,
and cysteine-rich domains; and P-IV enzymes have a lectin-
like domain linked by disulfide bonds to a P-III structure
[33]. The structural complexity of P-III enzymes has
resulted in greater functional diversity. They promote
Figure 2 Gene expression in the venom glands correlates well with protein abundance in the venom. In both cases the correlation was
strongly significant, although roughly half of the variance remained unexplained. These data show that mass spectrometry can provide quantitative
data on protein abundance in snake venom proteomes. A similar pattern can be seen using publicly available snake venom proteins from NCBI as a
protein reference (Additional file 8: Figure S1), suggesting that this technique should also work without species-specific transcriptomic data.
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activation, while inhibiting platelet aggregation. As a
general rule, P-III enzymes are more potent hemorrhagins
than P-I enzymes [33]. In addition to degrading vascular
endothelial basement membrane (hemorrhagins), col-
lectively, MPs exhibit diverse and variable combinations
of activities. Some anticoagulant metalloproteases degrade
only the fibrinogen Aα chain [34], while others degrade
one or more chains of both fibrinogen and fibrin with
varying specificity [34-36]. Still others release histamine
[37], antagonize platelet aggregation by different mecha-
nisms [38-41], or activate [42] or digest plasminogen [43].
Some are procoagulant, possessing Factor Xa-like activity
[44]. Few laboratories have exhaustively assayed MPs
for potential biological and biochemical activities; thus,
inferring such functions from structure is almost impos-
sible. The same may be said of SPs.
The Protobothrops transcriptome contained transcripts
for twelve P-II MPs and nine P-III MPs. One of the
P-II enzymes (MP 01) constituted 11.06% of all toxin
transcripts and collectively P-II transcripts accounted for
barely ~11.1% of the transcriptome (Additional file 9:
Figure S2; Additional file 1: Tables S1, Additional file 5:
Table S3, and Additional file 2: Table S4). P-III transcripts
were more abundant, comprising 15.8% of all transcripts.
Three sequences were homologous to hemorrhagic prote-
ases HR1A and B [45,46]. The Ovophis transcriptome
included seven P-II transcripts and three P-III transcripts.
In Ovophis, P-II transcripts represented only 1.6% of all
transcripts (Additional file 3: Table S2 and Additional
file 4: Table S5). P-III transcripts added another 2.6%. Thus
MPs comprised a mere 4.2% of the Ovophis transcriptome,
compared to 26.9% in Protobothrops (Figure 1, Additional
file 9: Figure S2 and Additional file 10: Figure S3;Additional file 3: Table S2, Additional file 5: Table S3, and
Additional file 4: Table S5).
Of the 21 Protobothrops MPs, peptides were sequenced
by mass spectrometry for 15, with coverage ranging from
31.1-91.4% of the respective transcripts (Additional file 1:
Table S1). Peptide coverage of Ovophis MPs ranged from
26.9-80.6% (Additional file 3: Table S2).
Phospholipases A2
The Protobothrops transcriptome contained four transcripts
for PLA2s (Additional file 1: Table S1), including a Lys-49
myotoxin (PLA2 4) [Accession #: AB851948] and a
weak neurotoxin similar to trimucrotoxin [47] (PLA2 2)
[AB848131]. PLA2 1 [AB848154] accounted for 26.7% of
all transcripts, while PLA2 2 amounted to an additional
5.5% (Additional file 1: Table S1 and Additional file 2:
Table S4). The Ovophis transcriptome contained two PLA2
transcripts; however, the more abundant transcript, PLA2
1, comprised only 0.65% of the transcriptome (Additional
file 3: Table S2 and Additional file 4: Table S5) [AB848270].
Peptides sequenced by mass spectrometry covered 98.3%
of PLA2 1, but no peptides were found for the minor
transcript.
Serine proteases
Of the 18 SP transcripts in the Protobothrops library
(Additional file 1: Table S1 and Additional file 2: Table S4),
only two (SP01 and SP 12) (FPKM% 2.6 and almost zero,
respectively) can be confirmed as complete (Additional
file 11: Figure S4). Several transcripts appear to encode
dysfunctional SPs. For instance, SP16 encodes 36 residues
and is bracketed on both ends by stop codons (Additional
file 1: Table S1; Additional file 11: Figure S4). Given that it
was expressed at a very low level and that no peptides
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unlikely to play any role in envenomation.
SP01, the most abundant SP transcript, corresponds to a
protein that appears in the literature under the names of
habutobin [48-51] and flavoxobin [52-56], a weakly throm-
bin-like enzyme of 242 amino acids that specifically releases
fibrinopeptide A from fibrinogen [55]. No information
is available with regard to possible kallikrein-like activity.
However, Yamamoto et al. [56] found that flavoxobin is
an active C3-convertase that selectively releases C3b and
C3a. It remains active in blood containing endogenous
protease inhibitors, and promotes massive C3 consump-
tion, and to a lesser extent, C5 cleavage. A kinin-releasing
enzyme, flavoviridiobin, is also known from this venom
[57]; however, since no sequence data are available, we
cannot identify it among our transcripts. Enzymatic digests
of crude venom effected with trypsin, chymotrypsin, and
Glu-C (Pierce) yielded peptides that accounted for 94.6% of
the primary structure of SP01 (Additional file 1: Table S1;
Additional file 11: Figure S4). Reasonable peptide coverage
of transcripts as minor as 0.24% (SP11, 50.0%) was achieved
(Additional file 1: Table S1).
In contrast to the Protobothrops library, the Ovophis
library contained transcripts for 26 different SPs (Additional
file 1: Table S1 and Additional file 2: Table S4; Additional
file 12: Figure S5). Peptide coverage of 36% or above
was achieved for 22 of these, with coverage above 70% for
11 of them. Two transcripts (SP09 and 10) appear to be
plasminogen activators, while SP20 is most similar to
a kinin-releasing enzyme from the venom of Bothrops
jararaca. Serine proteases display numerous amino acid
substitutions, and the structural determinants that specific-
ally account for kinin-releasing activity are unknown [58].
The difficulty in assigning pharmacological activities to
specific sequence variations is immediately apparent upon
a cursory examination of Additional file 11: Figure S4 and
Additional file 12: Figure S5.
Wu et al. [59] reported a novel class of inactive serine
protease homologs (SPH) that displayed an arginine
substitution for His-43 of the catalytic triad. SP13 was
the only serine protease in our Protobothrops library that
showed this His→ Arg mutation (Additional file 12:
Figure S5, position 126); however, the Ovophis library
contained eight transcripts with His→ X substitutions
(Additional file 12: Figure S5, position 101). Two of these,
SP08 and SP22 showed His→ Lys substitutions; two
putative thrombin-like enzymes, SP16 and SP17 displayed
His→Asn substitutions, and SP07 had a His→Ala sub-
stitution. Numerous other sequence differences appear in
that transcript as well (Additional file 12: Figure S5). SPHs
from other sources have been shown to possess diverse
activities, so it is possible that inactive SPs in venoms have
developed other unknown functions, some of which may
be specialized for particular prey types.An inactive catalytic triad is but one of many structural
differences manifested by Ovophis SPHs (Additional file 12:
Figure S5). Almost all of the cysteine residues are in differ-
ent positions as well (Cys-102 has only moved to position
100, but most have shifted substantially more), although
within the group, most residues are conserved across most
sequences. SP07 is a marked exception in the latter regard
(Additional file 12: Figure S5). Another oddity among
these sequences is that four of them (SP01, 07, 23, and 26)
are truncated C-terminally with stop codons, despite the
fact that SP01 and 07 display expression levels of 9.6 and
7.1%, respectively. Wang et al. [60] reported that a Kentucky
population of Crotalus horridus lacks an acidic PLA2
because the codon for Tyr22 has mutated into a stop codon.
They concluded that low PLA2 expression levels in most
Crotalus horridus venoms can be attributed to translation
blockage. At this point, it is difficult to know how wide-
spread this phenomenon might be, but it is apparent that
these two Ovophis SPs are translated effectively since they
had ample peptide coverage (Additional file 3: Table S2).
L-amino acid oxidase
The Protobothrops transcriptome included two transcripts
for L-amino acid oxidase [AB848142, AB848143], compris-
ing 2.3% and 6.8% of all transcripts, respectively (Figure 1;
Additional file 1: Table S1). A single LAO transcript was
present in Ovophis glands [AB848269], representing 0.6%
of the transcriptome (Additional file 3: Table S2). Peptides
accounting for 84.6% and 70.8% of Protobothrops LAO 1
and LAO 2, respectively, and 78.7% of the Ovophis LAO
transcript sequence was identified by mass spectrometry
(Additional file 1: Table S1 and Additional file 3: Table S2).
Minor venom constituents
Cysteine-rich secretory proteins
Two CRISPs were identified in the Protobothrops transcrip-
tome (Additional file 1: Table S1 and Additional file 2:
Table S4). CRISP 1 [AB848115], (FPKM= 3.9%) for which
a complete transcript was obtained, is identical to triflin
[61], but CRISP 2 [AB851959] aligns best with a CRISP
bearing an EGF-like calcium-binding domain from the
venom of Crotalus adamanteus [62] (Additional file 2:
Table S4). However, the putative 39-residue EGF domain
in the C. adamanteus toxin does not align well with the
corresponding region of the Protobothrops transcript. The
latter contains only four acidic residues, compared with
nine in the C. adamanteus sequence. Only three of the
five C. adamanteus cysteine residues match, and the two
sequences require a two-residue gap to achieve even this
poor alignment. Therefore, we think it unlikely that
there is a functional EGF-like calcium binding domain
in the Protobothrops toxin. Moreover, no peptides were
sequenced for this odd CRISP, whereas 84.6% of CRISP 1
was sequenced.
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identified in the Ovophis transcriptome (Additional file 2:
Table S2) [AB848276], but sequenced peptides accounted
for 89.0% of its primary structure. It was most similar to a
CRISP from the venom of Bothriechis schlegelii [GenBank:
ACE73559.1].
CRISPs are generally not abundant components of snake
venoms, but they are widely distributed taxonomically.
Ablomin (Gloydius blomhoffii), triflin (Protobothrops
flavoviridis) and latisemin (Laticauda semifasciata) are
L-type Ca2+ channel antagonists of depolarization-induced
arterial smooth muscle contraction, but they do not affect
caffeine-induced contraction [61]; thus they promote
vasodilation and hypotension. Tigrin from “venom” of the
Japanese colubrid, Rhabdophis tigrinus, affected neither.
This is probably because Rhabdophis venom glands are not
secretory in nature. Instead, Rhabdophis glands sequester
toxins from the blood stream that are derived from the
toads that Rhabdophis eats [63]. Thus, tigrin is most likely
an amphibian toxin, intended for oral or gastric activity,
and not a snake toxin, designed for direct vascular action.
In contrast, patagonin, a CRISP isolated from the venom of
the colubrid, Philodryas patagoniensis, damaged murine
skeletal muscle [64].
Nerve growth factor
Both habu transcriptomes contained a single, complete
transcript for nerve growth factor [Pf: AB848144; Oo:
AB848271] (Additional file 1: Table S1 and Additional
file 3: Table S2). The Protobothrops transcript accounted
for 0.7% of all transcripts while the Ovophis transcript
accounted for 0.5%. Both transcripts are translated and
peptides were isolated by mass spectrometry. NGFs func-
tion as arginine esterases [65,66], so they probably contrib-
ute to venom hypotensive activity via nitric oxide liberation
and histamine release [67,68]. Mouse salivary NGFs
activate plasminogen, their only known action upon a
biologically important, non-neural substrate [69,70], but it
is not clear whether snake venom NGFs can also do this.
If so, they would hinder blood clotting.
C-type lectins
Snake venom C-type lectins, or snaclecs [71] are commonly
found in pit viper venoms. These proteins differ from clas-
sical C-type lectins in that they lack the calcium and sugar-
binding loop and instead bind to a large variety of proteins
and receptors involved in hemostasis, including coagulation
factors IX and X and various blood platelet receptors [72].
They may consist of one, two, or four αβ heterodimers,
and in some cases, the heterodimer is incorporated into a
metalloprotease [73]. In many CTLs, dimers are formed by
domain swapping between subunits [73].
CTL pharmacology is quite complex. Taniuchi et al. [74]
found that flavocetin A actually induces formation of smallplatelet aggregates, but the dose-dependency is bell-shaped,
with a maximum effectiveness at 1-2 μg/mL. Clemetson
[72] lamented that because so much venom research is
now done at the transcriptional level, the protein chemistry
and pharmacology necessary to understand CTL diversity
has lagged way behind. In reality, the same could also
be said of any other toxin family that shows significant
diversification, such as 3FTxs, SPs, MPs, and PLA2s.
Venom C-type lectins may activate platelets or inhibit
platelet activation, but either mechanism serves the func-
tion of inducing thrombocytopenia. Because C-type lectins
are non-enzymatic, a 1:1 stoichiometry exists between these
toxins and their targets. Clemetson [72] noted that for this
reason, it is much more efficient to clear platelets by acti-
vating them than by inhibiting them. However, different
species of snakes employ both strategies, and it is probably
necessary to look at all the toxins in a given venom that
impact hemostasis, before drawing any conclusions.
Twelve Protobothrops CTL transcripts included three
α-chains and three β-chains homologous to flavocetin A,
an (αβ)4 inhibitor of von Willibrand factor-induced, GP1B-
mediated platelet aggregation [75,76] and convulxin, a
potent (αβ)4 inducer of platelet aggregation that binds
to GPVI [73] (Additional file 13: Figure S6; Additional
file 1: Table S1 and Additional file 2: Table S4). One of the
flavocetin A-like α-chains (CTL03α) and CTL07 F IX/X
displayed a number of sequence differences, including an
unusual C-terminus (CKFLRPR). Whether these have any
pharmacological significance is unknown. In addition to
toxins that target blood platelets, there were five A chains
and one B chain for proteins that bind to coagulation
Factors IX/X (Additional file 1: Table S1 and Additional
file 2: Table S4). Factor IX/X binding proteins inhibit blood
coagulation by blocking the host clotting cascade [77].
Seven Ovophis CTL transcripts apparently all encode
proteins that affect platelet activation (Additional file 3:
Table S2 and Additional file 4: Table S5; Additional file 13:
Figure S6). They are homologous to flavocetin A and
convulxin. We did not discover any Ovophis transcripts
that encode anticoagulant Factor IX/X-binding proteins.
Our Ovophis cDNA library contained one α-chain, CTL1α,
similar to the α-chain of flavocetin A (Protobothrops
flavoviridis) and the convulxin A- and C-chains (Crotalus
durissus terrificus) (Additional file 13: Figure S6). CTL1α
is most like crotacetin (Crotalus durissus terrificus. It
represented 0.16% of all transcripts. In addition, there
were six β-chains, homologous to the flavocetin A β-chain
and the convulxin B- and D-chains (Additional file 13:
Figure S6; Additional file 3: Table S2). Together these
seven CTLs represented 0.47% of all transcripts.
Bradykinin-potentiating peptides
A single bradykinin-potentiating peptide (BPP) was se-
quenced from Protobothrops venom using mass spectrometry
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the existence of a BPP proposed by Higuchi et al. [78], on
the basis of a cDNA transcript. A second possible BPP
(VVVQPHESPAGGTTA) was also sequenced, but to date,
no other BPPs have been found with proline immediately
after the N-terminal pyroglutamic acid, making this se-
quence suspect. Moreover, the VVV-sequence, N-terminal
to the glutamine, and the C-terminal AGGTTA-sequence
are highly questionable. Possibly this peptide could be
processed to QPHESP. This possible BPP is located at
the C-terminus of our BPP transcript; however, our BPP
transcript is incomplete, since it lacks a stop codon and it
does not include the C-type natriuretic peptide-coding
region reported by Higuchi et al. [78] (Figure 3).
Our Protobothrops transcript [AB851926] also contains
the second BPP sequence reported by Higuchi et al. [78],
although this BPP was not identified by mass spectrometry.
They posited the existence of two BPPs based on the
assumptions that such sequences should possess glutamine
at the N-terminus and proline at the C-terminus, and
should be about 11 residues in length. In fact, BPPs from
three to 14 residues have been reported [79,80] (Additional
file 14: Figure S7). Both the Higuchi Protobothrops
transcript and ours suggest another probable BPP with the
sequence QWMPGGRPPHHIPP (Figure 3). The Gloydius
transcript of Higuchi et al. [78] also contains a tripeptide
(QWS) that occurs in five locations at the end of the
BPPs that they predicted (Figure 3). Two tripeptides
from Bothrops insularis venom having pyroglutamic
acid at the N-terminus (QQK, QKW) were sequencedFigure 3 Alignment of the Protobothrops flavoviridis [AB851926] and
of Higuchi et al. [78] for Protobothrops flavoviridis and Gloydius blomh
mass spectrometry in the present study are shown in red. Possible addition
sequences are highlighted in aqua.by Cintra et al. [79], and these peptides were shown to
have bradykinin-potentiating activity on guinea pig ileum
(Additional file 14: Figure S7). It is possible that the
peptide QWS is likewise biologically active. Other tripep-
tides are found in the Higuchi Protobothrops and Gloydius
transcripts and in our Ovophis transcript. These have the
sequences QER (Protobothrops) and QAR (Gloydius and
Ovophis) (Figure 3, residues 281-283). All of these are
immediately N-terminal to nonapeptides that could also
be BPPs (Figure 3, residues 284-292). These sequences are
as follows: Pf, QKWGRMVQP; Gb, QNWARMVNP; Oo,
QKWGRMVPP.
In addition to being truncated on the C-terminal end
relative to the Higuchi transcript, our transcript displays a
significant N-terminal extension, containing three additional
possible BPPs (Figure 3). These have the sequences QRRV
HGGERIWP, QSARLDSTRLGSAP, SRPPSLPAPAQP; how-
ever, additional work will be necessary to determine whether
these sequences are actually hypotensive and whether they
are actually expressed in habu venom.
Our Ovophis BPP transcript [AB852004] displayed a
C-terminal stop codon, but was incomplete on the N-
terminal end. However, the Ovophis transcript did contain
a sequence for a C-type natriuretic peptide (GVAKGCF
GLKLDRIGTMSGLGC) that was identical to that reported
for Gloydius blomhoffii venom [78] (Figure 3). It differed
at five residues from the Higuchi Protobothrops transcript
(Figure 3).
When mass spectrometry was used to analyze crude
Ovophis venom for the presence of BPPs, the sequenceOvophis okinavensis [AB852004] BPP/CNP transcripts with those
offii. Peptides posited by Higuchi et al., or actually sequenced by
al BPPs identified in the present study are shown in violet. CNP
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GPPIPP) were isolated. This sequence does not occur in
our truncated transcript; however, it is nearly identical to
a proposed BPP from the N-terminal end of a BPP-CNP
transcript from Gloydius blomhoffii (RPPGPPIPR) [78,81]
and from Bothrops jararaca venoms [80] (Figure 3 and
Additional file 14: Figure S7).
Potency of bradykinin-potentiating peptides (BPPs)
increases ~200-fold if the C-terminal proline residue is
doubled [82]. While the C-terminal tripeptide of a BPP
from Gloydius halys venom was shown to be essential for
its activity, removal of the N-terminal pyroglutamate
residue made it twice as potent [82]; thus, while the N-
terminal pyroglutamate common to BPPs (Additional
file 14: Figure S7) may prevent their rapid degradation
by prey aminopeptidases, it is actually an impediment to
bradykinin potentiation. Interestingly, bradykinin-potentiat-
ing activity is not correlated with inhibition of angiotensin-
converting enzyme (kininase II) activity [82,83], which is
much too slow to be relevant to envenomation.
Various studies have shown that bradykinin potentiation
and inhibition of somatic angiotensin-converting enzyme
(sACE) by pit viper hypotensive peptides are independent
biochemical activities [84-89]. The presence of paired
proline residues at the C-terminus and a pyroglutamic acid
residue at the N-terminus are not the only requirements
for bradykinin-potentiating activity or sACE inhibition.
Guerreiro et al. [86] have shown that argininosuccinate
synthetase is activated by a BPP from Bothrops jararaca
venom, indicating that nitric oxide formation represents
yet another means by which BPPs promote hypotensive
shock to limit prey flight [1].Phospholipase B
Phospholipase B (PLB) activity was first reported in snake
venoms by Doery and Pearson [90], who confirmed its
presence in the venoms of Naja naja, Pseudechis
porphyriacus, and Agkistrodon piscivorus. In 1987, PLB
from Pseudechis colletti venom was characterized for the
first time [91]. No venom PLB sequences were reported
until 2011, when transcripts were isolated from venoms of
Drysdalia coronoides [92] and Crotalus adamanteus [62].
While PLB accounted for only 0.06% of all transcripts
in those species, it represented 0.14% of Protobothrops
[AB848155], and 0.15% of Ovophis transcripts [AB848284,
AB848285] (Additional file 1: Table S1, Additional file 3:
Table S2, Additional file 5: Table S3). Peptides covering
26.1% of the Protobothrops sequence and 50.5% and 61.6%
of the two Ovophis sequences, respectively, were isolated
by mass spectrometry (Additional file 1: Table S1 and
Additional file 3: Table S2; Figure 4). To the best of our
knowledge, these are the first protein sequence data for
any snake venom PLB.Feola et al. [93] found that in rabbits, i.v. injections of
phosphatidylethanolamine (PE) and phosphatidylserine
(PS) caused significant hypotension, cardiac arrhythmias,
bronchospasm, activation of intravascular coagulation,
complement, platelets, and leukocytes with release of hista-
mine, serotonin, and thromboxane at a dose of 0.10 mg/kg
and caused cardiac arrest and death at a dose of 0.30 mg/kg.
All of these effects are consistent with snake venom
envenomation strategies [1]; however, it is not clear
whether intact PE and PS are released from cell mem-
branes by pit viper venoms. Kinoshita et al. [94] found that
PS and PE were not released from membranes by purified
Protobothrops flavoviridis phospholipase A2; however, one
would not really expect this, and venoms contain many
other components in addition to phospholipase A2. What
is more, prey tissue destruction by venom components lib-
erates many endogenous compounds, further complicating
the picture. At present, the role of PLB in envenomation
remains unclear, beyond its generalized hydrolysis of cell
membrane phospholipids.
Phosphodiesterase
The Protobothrops transcriptome contained four phospho-
diesterase (PDE) transcripts, ranging from 0.33-0.56%
of all transcripts (Additional file 1: Table S1), which com-
prised, in aggregate, 0.2% of the transcriptome [AB848150,
AB848151, AB848152, AB848153]. Peptides covering 53.4-
56.8% of the four PDE sequences were sequenced by
MS. PDE was less diversified in Ovophis (Additional file 3:
Table S2). Two PDE transcripts accounted for a negli-
gible portion of the Ovophis transcriptome [AB851989,
AB851990]. Sequenced peptides accounted for only 7.8-
13.0% of the two PDE sequences.
Vascular endothelial growth factor-like proteins
Five VEGF isoforms comprised just over 0.008% of all
Ovophis transcripts [AB852007, AB852008, AB852009,
AB852010, AB848274], while three Protobothrops tran-
scripts totaled 0.32% of that transcriptome [AB848141,
AB851940, AB851941] (Additional file 1: Table S1,
Additional file 2: Table S4, Additional file 3: Table S2,
Additional file 4: S5, Additional file 5: Table S3). Fourteen
unique peptides were isolated for Protobothrops VEGF 1,
accounting for 81.1% of its sequence. Fourteen peptides
were also sequenced from Ovophis VEGF 5, amounting to
60.3% coverage (Additional file 1: Table S1 and Additional
file 3: Table S2).
Both venomes contain transcripts for several structural
subclasses of VEGFs, although owing to the great diversifi-
cation of these sequences, classification is difficult. For
instance, Ovophis VEGF 1 possesses a 24-residue insert
seen in no other sequence (Figure 5). Ovophis VEGF 1 and
2 and ProtobothropsVEGF 2 all possess long C-terminal ex-
tensions and align well with human VEGF-A165 (Figure 5).
Figure 4 Alignment of the 5‘ end of the Protobothrops flavoviridis phospholipase B (PLB) transcript [AB848155] with the entire Ovophis
okinavensis PLB transcript [AB848284]. Residues highlighted in orange represent the putative Crotalus adamanteus signal peptide sequence
[62]. Chymotryptic peptides are shown in purple. Tryptic peptides are in blue. Glu-C peptides are in green. Peptides highlighted in gray were from
a venom sample that was undigested. The peptides were naturally occurring, probably as a result of auto-catalysis. Peptide coverage of the
Ovophis transcript [AB848284] was 50.5%. To the best of our knowledge, these are the first peptidyl data for a snake venom PLB.
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that venome, at 0.222% (Additional file 3: Table S2).
Human VEGF-A binds to fms-like tyrosine kinase-1
(VEGF Receptor-1) (VEGFR-1) and to kinase insert do-
main-containing receptor (VEGFR-2), but not to VEGFR-3Figure 5 Alignment of VEGF sequences. Owing to the diversification
Ovophis VEGF 1 [AB852007] possesses a 24-residue insert seen in no other
[AB848141] are homologous to vammin, from the venom of Vipera ammod
residues that bind heparin [102]. Both vammin and VR-1, a VEGF from Dab
Another subclass of VEGF including Ovophis VEGF 3-4 [AB852009, AB85201
no C-terminal extension, or an extremely short extension corresponding to
Protobothrops VEGF 2 [AB851940]. These are significantly shorter than barie
with it or with vammin.(fms-like-tyrosine kinase-4) [95-98]. VEGF-A induces
vasodilation mediated by nitric oxide [99] and increases
vascular permeability 50,000-fold more potently than hista-
mine [100]. In addition, VEGF-A promotes tachycardia,
hypotension, and diminished cardiac output when injectedof this toxin family, classification of venom VEGFs is difficult.
sequence. Ovophis VEGF 5 [AB848274] and Protobothrops VEGF 1
ytes. All three of these display short C-terminal extensions of 16-17
oia russellii venom, enhance vascular permeability with great potency.
0] and Protobothrops VEGF 3 [AB851941] comprise a subclass with
the C-terminus of Ovophis VEGF 1-2 [AB852007, AB852008] and
tin, from the venom of Bitis arietans [98], and they do not align well
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Protobothrops VEGF 2 have similar pharmacology, as
these symptoms are consonant with snake envenomation
strategies [1].
Ovophis VEGF 5 [AB848274] and Protobothrops VEGF 1
[AB848141] are homologous to vammin, from the venom
of Vipera ammodytes. All three of these display short
C-terminal extensions of 16-17 residues that bind heparin
[102] (Figure 5). Vammin specifically recognizes VEGFR-2
[98]. Both vammin and VR-1, a VEGF from Daboia russellii
venom, enhance vascular permeability with greater potency
than does VEGF-A165 [98]. Additionally, Yamazaki et al.
[103] have shown that a Lys-49 PLA2 without catalytic
activity further enhances the vascular-permeability pro-
moting capacity of vammin.
Ovophis VEGF3-4 and Protobothrops VEGF3 comprise a
subclass with no C-terminal extension, or an extremely
short extension corresponding to the C-terminus of
Ovophis VEGF 1-2 and Protobothrops VEGF2 (Figure 5).
These are significantly shorter than barietin from the
venom of Bitis arietans [98], and they do not align well
with it or with vammin (Figure 5).5’-Nucleotidase
Both transcriptomes included a single transcript for 5’-
nucleotidase (Additional file 1: Table S1 and Additional
file 3: Table S2) [Pf: AB848147; Oo: AB851991]. In both
transcriptomes 5’-nucleotidase was a negligible constituent.
Mass spectrometry identified 51 venom peptides account-
ing for 63.3% of the expected sequence of the mature
Protobothrops protein, while 65 unique peptides were
detected in Ovophis venom, accounting for 12.9% of the
5’-nucleotidase in that venom.
5’-nucleotidase is ubiquitous in snake venoms [104-107],
suggesting a central role in envenomation. This enzyme is
known to cleave a wide variety of ribose- and deoxyribose-
containing nucleotides [108-110]. It is most active against
AMP [109,110] supporting the central role of adenosine in
envenomation proposed by Aird [1]. 5’-nucleotidase does
not cleave flavin mononucleotide, or cAMP; however, these
are hydrolyzed by venom PDE.Galactose-binding lectins
In contrast to C-type lectin-like proteins (CTL), galactose-
binding lectins (GBLs) possess intact calcium and galact-
ose-binding loops [72]. GBLs are similar in size to CTL-like
proteins and are also dimeric. However, instead of
interacting with platelets, GBLs aggregate erythrocytes
[111,112]. For this reason, most authors, starting with
Gartner et al. [112], have assumed that the presence of
GBLs in venom is related to envenomation; however,
several lines of evidence raise the possibility of a role unre-
lated to prey immobilization or digestion [1].GBLs have been shown to be strongly mitogenic
[113-115]. Their mitosis-inducing effects on lymphocytes
were found to be comparable to those of concanavalin A
[115]. Fry and Wüster [116] noted that GBLs appear to be
basal phylogenetically among venomous snakes, whereas
CTL-like proteins appear only in the Viperidae. Unlike
CTL-like proteins, GBLs display very little sequence
variability, suggesting that they are not under selective
pressure to diversify, as CTL-like proteins are [117].
Lectins with similar sugar specificity are found in many
tissues [118]. In Protobothrops and Ovophis, GBLs are
expressed at very low levels (Additional file 1: Tables S1
and Additional file 3: Table S2) [Pf: AB848130; Oo:
AB848277]. Ogilvie et al. [119] likewise found low
expression levels for GBLs in Bothrops atrox (0.2%) and
Dendroaspis jamesonii (0.4%) venoms, with a somewhat
higher level (0.8%) in Lachesis muta venom. Lomonte et al.
[120] found that the GBL from Cerrophidion godmani
venom exhibited edema-forming activity in mice, but
concluded that with its low potency and low abundance,
it probably plays relatively little role in envenomation.
The aforementioned data suggest that GBLs may exist
in venom as mitogens to regulate synthetic activity in
the glandular epithelium itself. If this view is correct,
hemagglutinating and edematogenic activities would be
fortuitous, but of secondary importance. Nonetheless, the
relative importance of such activities might vary among
taxa.
Aminopeptidases
Aminopeptidase N plays a significant role in preventing
hypertension by degrading Angiotensin III to Angiotensin
IV [121]. The role of aminopeptidase A in blood pressure
regulation appears to be more complex. APA degrades
Angiotensin II to Angiotensin III [122]. When acting at
peripheral sites, Angiotensin III is less potent hypertensive
than Angiotensin II [122], but in central sites, Angiotensin
III raises blood pressure more effectively than Angiotensin
II [122,123].
Various lines of evidence suggest a role for APA in
promoting hypotension in situations analogous to en-
venomation. Systemic administration of APA in spontan-
eously hypertensive rats [124] or hypertensive rats infused
with angiotensin II [125] reduced their blood pressure.
Administration of amastatin, an APA inhibitor, raised blood
pressure in normotensive rats [126].
To date nominal aminopeptidases A and N have been
isolated from pit viper venoms, although expression levels
appear to be generally low, and many venoms apparently
may not contain either. In the present study, Ovophis
venom contained a complete transcript for Aminopeptidase
A [AB848288], while Protobothrops venom contained
two APA transcripts [AB848148, AB848149]. However,
the Ovophis Aminopeptidase A transcript comprised only
Aird et al. BMC Genomics 2013, 14:790 Page 12 of 26
http://www.biomedcentral.com/1471-2164/14/7900.002% of all transcripts, while the two more abundant
Protobothrops transcripts together comprised 0.073%; hence
both are very minor venom constituents. Ovophis APA and
Protobothrops APA 1 were closely related to that reported
from Gloydius brevicaudus venom [127], differing at only
24 and 22 residues out of 953, respectively.
Tu and Toom [128] found that nearly all venoms
hydrolyze L-leucyl-β-naphthylamide, but that there exists
great variation in activity levels. Aird [1] suggested that the
principal function of leucine aminopeptidase (arylamidase)
(LAP) is digestive and that it links the hemorrhagic venom
metalloproteases and other venom and endogenous prey
peptidases, to L-amino acid oxidase in order to potentiate
H2O2 liberation, resulting in hypotension and anticoagu-
lation. It is probable that numerous other amino- and car-
boxypeptidases in plasma also pass free amino acids to
LAO. Clearly the release of Leu from circulating peptides
is not solely dependent upon venom LAP. This may partly
explain the variation in LAP levels that exists among
different venoms [107]. If LAP is abundant in prey tissues,
there may not be great selection pressure governing its
level of expression in venoms. In the two transcriptomes,
LAP was a very minor component [Pf: AB851938; Oo:
AB851994] (Additional file 2: Table S4 and Additional
file 4: Table S5).
The Protobothrops transcriptome possessed two ami-
nopeptidases that show similarity to Aminopeptidase N
[AB851954, AB851955] (Additional file 2: Table S4), but
some of these did not manifest much similarity to the two
Gloydius brevicaudus enzymes [127]. They also showed
similarity to Aminopeptidase A, so without careful bio-
chemical analyses it is impossible to classify them precisely.
Furthermore, it may be that the aminopeptidase nomencla-
tural system devised for use with human enzymes, may
not be applicable to snake venom aminopeptidases.
Dipeptidyl peptidase IV
Dipeptidyl Peptidase IV (DPP IV) was first discovered in
venoms of various Micrurus species by Jorge da Silva and
Aird [107]. It was also detected in the venoms of two
other elapids, Bungarus multicinctus, Naja naja, and in
that of the Brazilian crotaline, Bothrops moojeni. DPP IV
titers varied by more than 4x among the different venoms.
DPP IV is believed to function in envenomation by blunting
a hypertensive response on the part of envenomated prey
[1]. Ogawa et al. [129] published the first snake venom
DPP IV primary structures, a pair of isomeric sequences
derived from cDNA libraries of Gloydius brevicaudus
venom glands. They determined that the signal peptide
was not removed from these sequences. Later Ogawa et al.
[130], showed that DPP IV, is actually secreted membrane-
bound in exosomes. These micro-vesicles probably account
for the “pre-peak” that elutes well ahead of the largest
proteins when snake venoms are fractionated using gelfiltration chromatography [131,132]. Exosomes were later
shown to be present in human saliva as well [133]. DPP
IV is nearly ubiquitous among elapid and viperid venoms,
but it exhibits great quantitative variability even among
full siblings [134].
The Protobothrops flavoviridis DPP IV sequence
[AB851922] comprises 751 residues, like those from
Gloydius, while the Ovophis sequence has 752 [AB848286].
Nonetheless, the Protobothrops and Ovophis sequences are
more similar to each other than to the Gloydius sequences
(Additional file 15: Figure S8). The Protobothrops sequence
is missing one of a pair of asparagine residues present in
the other three sequences, but both the Protobothrops and
Ovophis sequences have a leucine residue that is missing in
the Gloydius sequences (Additional file 15: Figure S8). No
DPP IV peptides were discovered with mass spectrometry
following enzymatic digestion of Protobothrops venom;
however, three unique peptides accounting for 4.6% of the
Ovophis DPP IV sequence were isolated. Venoms were
well centrifuged before sample digestion, which probably
pelleted the exosomes; thus it is surprising that any Ovophis
peptides were identified.
Glutaminyl cyclase
QC cyclizes, and thereby protects the N-termini of bio-
logically active peptides, such as the BPPs [135], some
metalloproteases [136-138], and the B and C chains of the
acidic subunit of crotoxin homologs [139,140]. No direct
role in envenomation has been suggested for QC to date.
However, while cyclization protects these peptides against
degradation by prey plasma aminopeptidases, in the case
of BPPs, bradykinin-potentiating potency is reduced by
half [82].
A total of five snake venom QC cDNAs have been
sequenced to date. Two of these belong to colubrids of
the Genus Boiga [141] and the other three have been
sequenced from crotalids on three different continents
(Gloydius blomhoffii, Bothrops jararaca, and Crotalus
adamanteus).
The present study adds eight additional sequences, of
which a couple are distinctly different from those previously
published. The Protobothrops sample contained four QC
transcripts for two pairs of toxins [AB848133, AB848134,
AB851933, AB851934]. The two identical long Protobo-
throps transcripts show near identity with other published
crotalid sequences (Figure 6). However, as confirmed by
the presence of stop codons, two other identical short
sequences are missing the N-terminal 37 residues of the
longer sequences. The next eight residues of the short
sequences are unique, but thereafter they are identical
to the long sequences (Figure 6). Pawlak and Kini [141]
reported a similar, though less extensive deletion in
the Boiga dendrophila QC; thus it is clear that this
sort of alternate splicing/post-translational modification
Figure 6 Alignment of four Protobothrops and two Ovophis glutaminyl cyclase (QC) sequences with bovine QC and with sequences
reported from two colubrid and three additional crotalid venoms. The two long Protobothrops transcripts [AB848133 and AB848134] show
near identity with other crotalid sequences, except for an N-terminal 15 residues upstream of the N-terminal methionine. The short Protobothrops
sequences [AB851933, AB851934] are missing the N-terminal 37 residues of the longer sequences. The next eight residues of the short sequences
(QC 3-4) are unique, but thereafter they are identical to the long sequences. Ovophis venom also contains two QC [AB852014, AB852015] sequences,
but owing to the lack of an N-terminal stop codon, no conclusions can be drawn regarding their length. Positions 18 and 47 differentiate Boiga from
the crotalids. Positions 27, 294, 298, and 300 are variable across the different taxa.
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also contains four QC sequences [AB852014, AB852015,
AB851985, AB851986], but because all are incomplete,
no conclusions can be drawn regarding their length.
The most highly expressed of these four represented only
0.008% of all transcripts (Additional file 3: Table S2),
consistent with an indirect role in envenomation. Peptides
were isolated for all four Protobothrops QCs, but only one
of the Ovophis isoforms.
Hyaluronidase
Hyaluronidase is not a major constituent of either venom.
A single complete transcript was found in the Protobothrops
library [AB851937], while two complete Ovophis transcripts
were sequenced [AB851977, AB851978]. No hyaluroni-
dase transcript was more abundant than the cutoff for
contaminants and no peptides were isolated from either
venom. Venom hyaluronidase has been deemed a
“spreading factor” because its degradation of the extra-
cellular matrix enables other venom constituents, such
as metalloproteases and phospholipases, to attack add-
itional tissues [142,143]. As such, hyaluronidase probably
serves primarily to digest the prey.
Three-finger toxins
Protobothrops venom, but apparently not that of Ovophis,
contains a three-finger toxin (3FTx) [AB851958]. This
sequence is most closely related to a transcript reported
from Sistrurus catenatus edwardsi venom [144] and to
candoxin isolated from the venom of an elapid, Bungarus
candidus [145] (Figure 7). 3FTxs were not detected in an
earlier study of Sistrurus catenatus barbouri venom [146],
and they have not been observed in many other venomics
studies of pit vipers [62,147-152]. Other studies have
located 3FTxs by transcriptomic means, but not by
proteomics approaches [15]. This is not surprising, given
their low expression levels in many taxa (0.8% in Sistrurus
catenatus venom [144]). While 3FTxs are minor compo-
nents of most pit viper venoms, relatively high expression
levels have been reported in some species. In a study of
Caribbean pit vipers, using Roche 454 sequencing
technology, Durban et al. [32] reported considerable
variability (Crotalus simus, 12.7%, western Bothrops asper,
4.7%; Bothriechis schlegelii, 3.6%; eastern Bothrops asper,0.8%; Cerrophidion godmani, 0.6%; and Atropoides picadoi,
0.4%).
The Protobothrops 3FTx differs slightly in its disulfide
bond structure from all known 3FTxs (Figure 7). It shares
a cysteine residue in position 18 with the 3FTx from
Sistrurus catenatus edwardsi venom; however, Cys-11,
which is linked to Cys-18 in the Sistrurus toxin, in the
Deinagkistrodon acutus short neurotoxin, and in candoxin,
occurs at position 9 in the Protobothrops toxin (Figure 7).
Enzymes involved in purine and pyrimidine biosynthesis
Aird [1] explained the neuromodulatory and hypotensive
roles of purine nucleosides in the pharmacology of snake
envenomation. A later study quantified purine and pyr-
imidine nucleosides in a wide variety of elapid, viperid,
and crotalid venoms [31]. Possible roles of uridine and
cytidine in envenomation are less clear than those of
purine nucleosides. Because nucleosides are endogenous
regulatory substances in all vertebrates, it is impossible
for any prey species to develop resistance to them; thus
they represent the perfect predatory biochemical weapon.
However, their endogenous nature also means that the
enzymes involved in nucleoside biosynthesis would be
expected in any venom gland transcriptome, regardless
of whether nucleosides are actually secreted into the
venom in quantities relevant to envenomation. As a result,
no venomics studies to date have specifically looked for the
presence of nucleoside biosynthetic enzymes. Instead they
have been treated as “housekeeping” genes. In fact, only
Rokyta et al. [62] have reported the sequences of adenylo-
succinate synthetase, adenylosuccinate lyase, IMP dehydro-
genase, GMP synthetase, nucleoside monophosphate kinase,
nucleoside diphosphate kinase, or CTP synthetase.
In both transcriptomes, we found transcripts for all four
of the enzymes required to synthesize AMP and GMP
from IMP [adenylosuccinate synthetase, Pf: AB851944;
Oo: AB851992, AB851995; adenylosuccinate lyase,
Pf: AB851928; Oo: AB851974; IMP Dehydrogenase,
Pf: AB848116; Oo: AB851975, AB851979, AB852003; GMP
synthetase, Pf: AB851932, AB851936, AB851946, AB851952;
Oo: AB851972, AB851983, AB851999] (Additional file 1:
Table S1 and Additional file 2: Table S4). The monopho-
sphates may then be dephosphorylated by a variety of
non-specific phosphatases or by venom or endogenous
Figure 7 Alignment of the Protobothrops flavoviridis three-finger toxin [AB851958] with selected sequences from colubrid, elapid, and
viperid venoms. Not surprisingly, the Protobothrops sequence aligns most closely with that from Sistrurus, one of only two other crotalid 3FTx
sequences available to date. Both the Protobothrops and Sistrurus sequences share an N-terminal sequence, EPGYT; however, the first two Cys
residues in the Sistrurus sequence occur in positions 8 and 11, whereas the Protobothrops sequence has paired Cys residues at positions 8 and 9.
The Protobothrops sequence also has a Pro residue in position 12 which does not occur in the Sistrurus mRNA. Based upon the mapping of
disulfide bonds in candoxin, the elapid 3FTx most similar to the crotalid toxins [145], it appears that in the Sistrurus toxin Cys-11 is bonded to
Cys-18, whereas in the Protobothrops toxin, Cys-9 is bonded to Cys-18 (red arrow), but these tentative assignments require experimental
confirmation. All other disulfide bonds are indicated with black arrows.
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enzymes, nucleoside diphosphate kinase [Pf: AB851920,
AB851929; Oo: AB851996, AB852013] and CTP synthetase
[Pf: AB851957, AB851927, AB851931; Oo: AB851984,
AB851993] were found in both transcriptomes, but nu-
cleoside monophosphate kinase was detected only in
Protobothrops [AB851951](Additional file 2: Table S4).
All of these sequences were identical or nearly so to those
reported by Rokyta et al. [62,153].
Unfortunately, because both species in the present study
are crotalids, the confirmation of nucleoside biosynthetic
enzymes in the venome was less interesting than it might
have been. The crotalid envenomation strategy involves
liberation of endogenous prey purine nucleosides, but
the venoms themselves have a minimal nucleoside content
[1,31]. In contrast, some viperid venoms and mamba
venoms may contain nearly 9% purines by dry weight [31].
Thus in crotalid venomes, nucleoside biosynthetic enzymes
probably are largely metabolic in function. It would
be interesting to examine the transcript levels of these
enzymes in Bitis or Dendroaspis venoms by comparison.
Direct analysis of venom nucleoside levels would be
required to determine what level of mRNA expression
corresponds to a departure from metabolic function to
envenomation.
Acid Phosphomonoesterase
Acid PME comprised a negligible percentage of all
transcripts in both venoms (Additional file 2: Table S4
and Additional file 4: Table S5) [Pf: AB851930;
Oo: AB851982]. The sequences were most closely related
to a tissue PME from Anolis carolinensis. To the best ofour knowledge, these are the first snake acid PME mRNA
sequences reported.
Acetylcholinesterase
The Ovophis transcriptome included five acetylcholin-
esterase (AChE) transcripts that collectively amounted
to less than the contaminant cutoff for venom gland
transcripts, so its presence in the transcriptome may
be accidental (Additional file 4: Table S5) [AB852000,
AB852001, AB852002, AB851981, AB851973]. AChE
activity is considered characteristic of most elapid, but not
viperid venoms. AChE transcripts have been reported re-
cently in selected colubrid and dipsadid venoms [11,154].
These are the first reported crotalid transcripts.
Homologs of crotamine, GAP and crotasin
Crotamine, a highly basic 42-residue myotoxin was first
reported 75 years ago [155] in the venom of Crotalus
durissus terrificus. Homologs were later discovered in
various other rattlesnake venoms [156-160]. These proteins
display perplexing geographic distributional patterns [161]
and individual quantitative variation [131], and they are
products of duplicated loci [162]. Their physiological
targets have remained controversial [163-169] and new
biochemical activities continue to be discovered [170-176].
Myotoxin a, a crotamine homolog from the venom of
Crotalus viridis viridis, was shown to undergo temperature-
sensitive conformational transitions owing to cis-trans
isomerization of Pro-20 [177,178]. It is unknown whether
the isomers bind to different physiological targets.
Marquardt et al. [179] patented a crotamine homolog
called GAP (growth arresting peptide) with mitosis-arresting
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which, to date, has not been reported to contain a small
myotoxin. GAP seems to have gone unnoticed by the
toxinological community for the past 24 years, but crotasin,
a crotamine homolog with some of the structural features
of GAP was reported by Radís-Baptista et al. [180].
The present study isolated two GAP/crotasin-like
transcripts from the Ovophis transcriptome (Figure 8)
[AB852005, AB852006], but no crotamine- or crotasin-like
sequence was found in the Protobothrops transcriptome.
Crotasin/GAP-like proteins are significantly less basic than
the crotamine-like proteins, and they lack a Phe-Pro dipep-
tide (crotamine residues 12-13), as well as the N-terminal
Tyr of the latter. The two Ovophis transcripts differ
very significantly from each other and from both GAP
and crotasin (Figure 8). Though the exact location of the
N-terminal residue cannot be determined with certainty,
they both apparently possess the N-terminal disulfide bond
present in crotamine and GAP, but absent in crotasin, and
they are comparable in length to crotamine and GAP.
Crotasin lacks the N-terminal eight residues of crotamine
homologs. However, the signal peptide sequence for various
crotamine isomers [181] exactly matches the signal peptide
sequences of our Ovophis crotasin/GAP homologs. Both
Ovophis transcripts manifested near-zero transcription
levels, so it seems unlikely that these are functional venom
components, but it is clear that the sequence diversification
that Oguiura et al. [182] reported, applies to these tran-
scripts as well.
Waprins
Waprins belong to a family of proteins with diverse
activities that are structurally related to whey acidic
protein [183]. Other members of the family have anti-
bacterial activity and protease inhibitory activity [184,185].
Waprins discovered to date are small proteins of about 50
amino acids, containing four disulfide bonds [186]. Clauss
et al. [187] identified a segment of human chromosome
20, displaying 14 genes for proteins related to whey acidic
protein. They postulated that the resulting gene products
could potentially serve an anti-microbial function against
pathogenic bacteria, or that they might participate in the
regulation of endogenous proteases. They also opined that
kallikrein-like proteases are of particular interest.Figure 8 Alignment of two Ovophis transcripts [AB852005, AB852006
growth-arresting peptide [179], and crotasin [180]. All of these toxins u
The Ovophis transcripts share more features with crotasin and GAP, and the
24, 28, 29, 36, 38, 49, 53, and 55). They lack Met-50 and Trp-54 of the small
transcripts bore the sequence RVHGRTSFS upstream from the putative signThe protease inhibitory capacity of members of this
family suggests possible roles in envenomation, though to
date, no evidence has been presented for any of these
functions. Snake venom proteins belonging to the Kunitz/
BPTI family have been modified to serve as ion channel
inhibitors [188] and to chaperone neurotoxic PLA2s [189].
BPPs inhibit angiotensin I-converting enzyme to promote
hypotension [83,190], but also may act directly upon other
physiological targets to induce hypotension [191,192]. Some
of the bradykinin-potentiating peptides serve an interesting
dual role by inhibiting hemorrhagic metalloproteases in
the venom gland [193].
Pahari et al. [144] reported the first viperid waprin-like
protein in the venom glands of Sistrurus catenatus
edwardsi. However, the putative Sistrurus toxin comprised
a waprin domain fused to a Kunitz/BPTI domain. The
function of the encoded protein is unknown. It was repre-
sented by only a single transcript, so it is difficult to say
whether this toxin is biologically significant. This non-
enzymatic toxin was expressed at near-zero levels.
Rokyta et al. [62] reported a full-length waprin tran-
script in the venom of Crotalus adamanteus. Both the
Protobothrops and Ovophis transcriptomes contained tran-
scripts that were strongly homologous to the Crotalus waprin
[Pf: AB851939; Oo: AB852011] (Figure 9). Interestingly,
the Ovophis waprin has a C-terminal Pro-Met, instead of
the usual Pro-Leu/Val-Pro. One peptide representing 28%
of the transcript sequence was isolated (Additional file 3:
Table S2).
Both venoms also contained sequences that are related
to the Kunitz serine protease inhibitor domain of the novel
ku-wap hybrid toxin from Sistrurus catenatus edwardsi
venom [62] (Figure 9). All of these transcripts are incom-
plete and the three N-terminal transcripts show relatively
little overlap with the region of fusion in the Sistrurus
ku-wap toxin; however, all three of the putative ku-wap
homologs show the acidic and basic residues (positions
83-84) and other features of the Kunitz domain of the
Sistrurus toxin (Figure 9). They do not show strong hom-
ology to either α-dendrotoxin [194] or to bovine pancre-
atic trypsin inhibitor (Figure 9). They may be additional
examples of the ku-wap family; however, they appear to be
most closely related to vertebrate inhibitors of the tissue
factor pathway.] with myotoxin a [156] and its precursor, crotamine [155],
tilize the same scaffold with 35-48 residues and three disulfide bonds.
y are generally less basic than crotamine and myotoxin a (positions
myotoxins and Trp-56 of the myotoxins and GAP. Both Ovophis
al peptide (not shown).
Figure 9 Alignment of Protobothrops [AB851939] and Ovophis transcripts [AB852011] with crotalid waprins. Both transcriptomes
contained partial transcripts that were strongly homologous to the Crotalus adamanteus waprin.
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In vertebrates, blood coagulation is initiated by the tissue
factor (TF) pathway. This pathway is regulated primarily
by tissue factor pathway inhibitor (TFPI), a Kunitz serine
protease inhibitor that inhibits Factor Xa and thrombin
at concentrations as low as 2.5 nM, thus controlling
the generation of thrombin and ultimately, of fibrin
[195,196]. Platelet TFPI is believed to modulate intravas-
cular coagulation [197].
The Protobothrops transcriptome contained a single,
partial transcript [AB851921] and the Ovophis tran-
scriptome contained two, very short, identical transcripts
[AB851997, AB851998] that align well with a predicted
Anolis TFPI, and less well with the Ku-Wap fusion toxin
from Sistrurus catenatus edwardsi venom glands and with
bovine pancreatic trypsin inhibitor (Figure 10; Additional
file 2: Table S4 and Additional file 4: Table S5). The
Protobothrops TFPI transcript aligns well with both the
acidic N-terminus and the highly basic C-terminus of
human TFPIα [198] (Figure 10).
All three transcripts are expressed at vanishingly low
levels (~0.001% of all transcripts) and it seems extremely
unlikely that they function in envenomation; however,
peptides ranging from 6.3% to 11.9% of the Protobothrops
and Ovophis sequences were isolated. Most likely, these
are tissue transcripts related to snake vascular homeosta-
sis. If they serve any additional roles, they might inhibit
venom SPs in the gland, or they might inhibit prey throm-
bin, allowing venom SPs to clot fibrinogen improperly,
resulting in its rapid clearance by the prey's anti-clotting
cascade.
Paraoxonase
Paraoxon hydrolytic activity has been reported only in
the venom of Daboia russellii to date [199]. Venoms
of Naja naja, Crotalus adamanteus, and Agkistrodon
contortrix contortrix showed only trace level activity by
comparison. Three genes comprise the paraoxonase
gene family in humans. PON1 is largely associated with
high-density lipoprotein, but has organophosphatase,
arylesterase, or lactonase activities, and it hydrolyzes aFigure 10 Alignment of TFPI-like sequences. The putative Protobothrops T
carolinensis. It aligns best at the C-terminus and in the middle, except for a 27
two regions. Two partial transcripts from Ovophis venom glands [AB851997, A
Affinities of these toxins to bovine pancreatic trypsin inhibitor and to the Ku-Wwide array of substrates [200]. PON2 and PON3 are not
well studied, but PON2 is known to be a widely-distributed
cellular enzyme. Two transcripts were found in the
Protobothrops transcriptome, but none in Ovophis. Both
Protobothrops transcripts were expressed at near-zero levels,
suggesting that paraoxonase is not a venom component in
either of these species. The Protobothrops paraoxonase
isozymes share diagnostic residues with all three human
isozymes and are not clearly related to any one of them
[AB851924, AB851925].
Vespryns
Pung et al. [201] isolated a novel 12 kDa toxin from the
venom of the king cobra that acts centrally to induce
hypolocomotion and pain in mammalian prey. A toxin
from Lachesis muta venom [202] was the first crotalid
vespryn and a second was sequenced from Crotalus
adamanteus venom [62]. The Protobothrops transcrip-
tome contained a partial, 70-residue vespryn transcript
[AB851949], but the Ovophis transcriptome had none
(Additional file 16: Figure S9). No vespryn peptides were
sequenced. The Protobothrops vespryn is most closely related
to that from Lachesis, which also displays a four-residue
gap from positions 25-28. Only three of the first 70 residues
differ between these two toxins. The three crotalid vespryns
are all 28-32 residues longer at the N-terminus than the
two corresponding toxins from Ophiophagus hannah and
Pseudechis australis venoms [203].
Conclusions
Using two distantly related pit viper species with different
venom compositions, our study illustrates the power of
using next generation sequencing in combination with
LC/MS profiling for the study of venom chemistry. We
were able to detect a wide variety of venom components
in both cDNA and in the venom itself. Except for the
annotation of protein function, the analytic pipeline was
entirely self-contained and did not rely on publicly
available reference databases. Given the decreasing costs
of sequencing, and the increasing power of mass spec-
trometry, this approach will be increasingly useful forFPI transcript [AB851921] is most similar to a DNA sequence from Anolis
-residue deletion in the Protobothrops sequence, which separates these
B851998] are identical to that from Protobothrops in the middle section.
ap fusion toxin from Sistrurus catenatus edwardsi venom are weak.
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reference data, and also for detecting fundamentally
new venom components that might have been missed
by earlier investigations.
We show, for the first time, that the composition of
venom gland mRNA is linearly correlated with protein
composition of the venom. Although this finding is fairly
trivial by itself, especially given the amount of unexplained
variance observed in our correlation, it has several inter-
esting methodological implications. It appears that peptide
detection with LC/MS can potentially be used to quantify
individual proteins in venoms. This can allow high-
throughput screening of numerous venom samples pro-
viding comparative data on the abundance of various
components. Although probably not as sensitive or quanti-
tative as cDNA sequencing, at least without further refine-
ment, this approach permits non-invasive sampling, which
will be important for rare or endangered species. Crude
venom is also easier to collect and store than RNA, making
it possible to collect numerous samples in the field,
or to use archived venom samples. We are currently
conducting studies focused on improving the accuracy of
LC/MS-based venom peptide sampling and quantification,
and on developing better metrics.
We obtained similarly quantitative results using de novo
assembled transcriptomes and publicly available data
from NCBI for protein identification (Additional file 8:
Figure S1). This finding makes mass spectrometry useful
even for species without custom-made species-specific
reference transcriptomes. Although using publicly available
data prevents the discovery of novel proteins, public data
should be particularly useful for comparative studies, and
for investigation of snakes for which transcriptomes cannot
be obtained for whatever reason.
With regard to the utility of using mass spectrometry
for non-invasive, quantitative sampling, another pair of
studies report the isolation of intact mRNA directly from
venoms [204,205]. It remains to be seen how quantitative
this technique will prove to be and how useful it will
be for archival samples, especially those that have been
repeatedly frozen and thawed, but certainly it offers
exciting possibilities, especially in combination with mass
spectrometry.
The present study reports 103 venom or venom-related
cDNA sequences from the venom glands of Protobothrops
flavoviridis. Of these, 40 were previously known from the
literature, although this figure includes isomeric forms not
previously reported. Fifty-one sequences were similar to
those reported from other venomous snake taxa, but were
new for Protobothrops. An additional 12 have not previ-
ously been reported for any snake. In regard to Ovophis
okinavensis, 94 of the 95 cDNA sequences reported herein
are new for this species, and 13 have not been reported
previously for any snake. Peptides were sequencedfrom 100% of transcripts that were more abundant than
contaminants such as human keratin (Additional file 1:
Table S1 and Additional file 3: Table S2). Peptides were
also sequenced from at least 18 additional transcripts that
occurred below the contaminant level.
To the best of our knowledge this study also furnishes
the first peptidyl sequence data (peptides sequenced by
mass spectrometry) for venom phospholipase B and
5’-nucleotidase, and the first mRNA sequence data for
a snake acid PME, adenylosuccinate synthase, paraoxonase,
and a putative tissue factor pathway inhibitor. Novel crota-
sin/growth-arresting peptide/crotamine-like sequences are
reported from the Ovophis transcriptome. The Protobothrops
3FTx sequence is only the third such sequence reported from
a crotalid, but it differs in significant ways from the other
two sequences.
Dominated by PLA2, MPs, and LAO, adult Protobothrops
venom strategically promotes hemorrhage, hypotension,
incoagulable blood, and prey digestion, consistent with
mammalian predation. Ovophis venom, by contrast, is
composed principally of SPs and MPs (93.1% of all tran-
scripts) (Figure 1; Additional file 1: Tables S1, Additional
file 3: Table S2, Additional file 5: Table S3). Its compos-
ition is less readily interpreted, owing to inadequate
pharmacological data for venom proteases. This venom
apparently represents a hybrid strategy optimized for
frogs and small mammals, but the contributions of most
components cannot be unambiguously assessed at present.
Methods
Venom and reagents
Venom was extracted from one Protobothrops flavoviridis
and one Ovophis okinavensis at the Okinawa Institute of
Health and Environment. Four days later, venom glands
were excised from each specimen. Prior to gland removal,
the two snakes were anesthetized with chloroform until
they showed no righting reflex or tail-retraction reflex.
In pit vipers, the tail is always the last part of the body
to become anesthetized and the first to recover from
anesthesia. This euthanasia protocol complies with the
“Guidelines for Proper Conduct of Animal Experiments”
(Science Council of Japan, June 1, 2006).
Once the snakes were completely anesthetized, glands
and underlying skeletal muscle were quickly excised after
dissecting back the overlying skin. Each gland was imme-
diately placed into a pre-labelled 1.5 mL microcentrifuge
tube having a screw cap and an O-ring, and dropped into
liquid nitrogen. Samples were then stored at -80°C until
the following week.
Isolation of total mRNA from venom glands
Total mRNA isolation employed a Qiagen RNeasy Plus
Mini Kit and utilized the following procedure. Glands were
removed from storage and their masses were determined
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dropped into a 50 mL Falcon tube containing 3 mL of
Buffer RLT Plus containing 1% β-mercaptoethanol.
Additional buffer was added after homogenization was
begun. Ideally 600 μL of buffer should be used for every
30 mg of tissue. Accordingly, the 350 mg Protobothrops
gland was homogenized in 6.5 mL RLT buffer, but because
the Ovophis gland weighed just 100 mg, only 2 mL were
needed, but in the interest of prompt homogenization,
3 mL were used anyway.
Lysates were centrifuged 3 min at maximum speed and
600 μL were transferred to each of five gDNA Eliminator
spin columns. All ten samples were then processed accord-
ing to Qiagen’s instructions. Eluents from the five tubes
were pooled for each of the samples.
Next the Ambion LiCl RNA precipitation technique was
employed, after reserving 50 μL of each pool for analysis
on the Nanodrop ND-1000. Pellets were resuspended
10 mM Tris, 1 mM EDTA.
All four samples were diluted to bring them into the
25-500 ng/μL range for analysis on an Agilent Bioanalyzer
2100 using an RNA Nano 6000 chip. The pre-LiCl
Protobothrops sample had an RNA Integrity Number (RIN)
of 9.5, while the other three samples were all 10.0.cDNA synthesis and preparation of Illumina RNA-Seq
libraries with barcodes
Post-LiCl samples were used for first strand cDNA synthe-
sis. In 200 μL PCR tubes, 1 μL of each total RNA sample
was combined with 3 μL water and 1 μL of 10 μM Cap-
TRSA-CV primer (AAGCAGTGGTATCAACGCAGAGT
CGCAGTCGGTACTTTTTTCTTTTTTV). Samples were
incubated 3 min at 65°C, and then chilled on ice. Total
RNA concentrations for the Protobothrops and Ovophis
samples were 1,282 and 930 ng/μL, respectively.
Next the following were added to each tube: 2.0 μL 5x
first-strand synthesis buffer (Clontech ST0079), 0.5 μL
10 mM dNTP (Clontech ST0073), 1.0 μL 0.1 M DTT
(Invitrogen Y00147), 1.0 μL 10 μM template-switch primer
(RNA oligo Smarter IIA, Clontech ST0069), and 1 μL
Superscript II reverse transcriptase (Invitrogen). Tubes
were incubated 1 hr at 42°C. Reactions were terminated
by heating at 65°C for 15 min. Tubes were then placed on
ice and samples were diluted with 40 μL water prior to
cDNA amplification.
Eight tubes of each first-strand cDNA were prepared
for second-strand synthesis and amplification using an
8.5x master mix containing: 25.5 μL first-strand cDNA,
178.5 μL water, 25.5 μL 10x PCR buffer (10x Advantage
2 SA PCR Buffer (S3245), 6.375 μL 10 mM dNTP, 11.9 μL
cDNA Amplification primers (Clontech Nested Universal
primer A, ST0102), and 5.1 μL Advantage 2 polymerase
(Clontech).Using a thermocycler, samples were heated to 95°C
for 1 min. This was followed by 11 cycles of (95°C for
10 sec/68°C for 6 min). Then the temperature was reduced
to 72°C for 10 min, before cooling to 4°C. PCR products
were purified with a QIAquick PCR purification kit
(Qiagen). Products were analyzed on a Nanodrop ND-1000
to determine double-stranded cDNA concentrations.
Eight μL of each purified sample were loaded into a
1% agarose gel and electrophoresis was performed in 1x
sodium borate buffer (56.6 mM Boric acid, pH 7.5
adjusted with NaOH) at 100 V for 30 min. New England
Biolabs 2-log DNA Ladder (0.25 μL) was used to estimate
DNA size.
Tagmentation followed the Epicentre Nextera DNA Sam-
ple Prep Kit (Illumina-compatible) protocol in a one-third
size (6.7 μL) reaction volume. The following components
were assembled on ice: 4.2 μL and 4.65 μL nuclease-
free water (for the Protobothrops and Ovophis samples,
respectively), 16.7 ng target DNA in 10 mM Tris-HCl
(pH 7.5) with 1 mM EDTA, 1.35 μL 5X Nextera reaction
buffer HMW, 0.35 μL Nextera enzyme mix (Illumina-
compatible). The above reaction mixture was briefly vor-
texed, and incubated at 55°C for 5 min in an MJ Research
PTC-200 peltier thermocycler with a heated lid. Tagmented
DNA was purified using the Qiagen Min Elute protocol.
We used Buffer ERC in the MinElute Reaction Cleanup Kit
because it efficiently binds double-stranded DNA ≥ 70 bp
and removes enzymes, salts, and oligomers. The final
step was to add DNA barcodes and to enrich the library
following the Epicentre Nextera DNA Sample Prep Kit
(Illumina-compatible) protocol.
Sequencing and bioinformatics
Both libraries were sequenced in a single Illumina GAII
lane using 75-bp paired-end reads at OIST’s sequencing
center, according to the manufacturer’s specifications. After
quality filtering with Condetri (v. 2.0) [206] using the
default setting, the reads were assembled using the Trinity
RNA-seq suite [207,208]. FPKM values for the isoforms
were computed using the RSEM package [209] included
with Trinity. Using a threshold recommended by Mortazavi
et al. [210], we filtered low abundance transcripts with
FPKM less than 1, and used these as reference sequences
for the proteomic pipeline.
Reduction, alkylation, and digestion of venoms with
trypsin and chymotrypsin
Crude venom was centrifuged 10 min at maximum speed
(20,238 rcf). Reactions were performed in 200 μL PCR
tubes. Reduction was accomplished using a reaction
mixture that contained 37 μL ultrapure water, 1 μL venom
(200-300 μg protein), 2 μL 500 mM DTT in ultrapure
water, and 10 μL 500 mM Tris-HCl (pH 8.0). Tubes were
incubated 45 min at 60°C in the dark in a thermocycler.
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iodoacetic acid Na+ salt (Nacalai 19305-24) in ultrapure
water were added to each tube and mixed with pipetting
and gentle vortexing. Tubes were incubated 30 min at
37°C in the dark. Then 1 μL of 500 mM DTT was added
to quench the alkylation reaction. Next 4.5 μL of 200 mM
CaCl2 (Nacalai 06731-05) were added to each tube. An
additional 5 μL of 500 mM Tris-HCl (pH 8.0) were added
to maintain the pH and ionic strength. Finally, 10 μg of
trypsin (Pierce 90055) or chymotrypsin (Pierce 90056)
dissolved in 1 mM HCl were added to each tube. Tubes
were incubated 24 h at 37°C and then frozen at -30°C until
preparation for mass spectrometry.
Digestion of venoms with Glu-C
Reduction and alkylation of venoms were performed as
described above, except that instead of 500 mM Tris-HCl,
167 mM phosphoric acid/NaOH (pH 8.0) was used.
Furthermore, the enzyme was dissolved in ultrapure water,
rather than in 1 mM HCl. This enabled the enzyme to
cleave proteins adjacent to aspartic acid residues, as well
as glutamate residues. When the enzyme was dissolved in
1 mM HCl, it cleaved next to glutamate residues only,
despite the use of phosphate buffers for hydrolysis.
Unlike trypsin and chymotrypsin, Glu-C (Pierce 90054)
was inhibited by iodoacetate. It was necessary to desalt the
reaction mixture before enzymatic digestion. Desalting
was accomplished using Zeba Spin Desalting Columns
(0.5 mL, Pierce 89882). Because naturally-occurring small
peptides in venoms, such as bradykinin-potentiating
peptides are removed by these spin columns, samples of
crude venoms were also prepared for direct analysis by
mass spectrometry, after removal of large proteins.
NanoLC-mass spectrometric analysis
A Thermo Scientific LTQ Orbitrap hybrid mass spec-
trometer was used for MS data collection. The mass spec-
trometer was equipped with an HPLC (Paradigm MS4,
Michrom Bioresources, Inc.), an autosampler (HTC
PAL, CTC Analytics) and a nanoelectrospray ion source.
Each venom digest was desalted using a ZipTip C18/P10
(Millipore) prior to the NanoLC-MS run. Clean sample
was separated on a capillary reverse phase column (50 ×
0.15 mm, 3 μm, MS C18, Grace Vydac). A one-hour gradi-
ent (10% B to 30% B in 60 min, where solvent A is 2%
acetonitrile and 0.1% formic acid, and solvent B is 98%
acetonitrile and 0.1% formic acid, flow rate 2.0 μL/min)
was used for the peptide separation. The temperature of
the heated capillary was 200°C, and 1.70 kV spray voltage
was applied to all samples. The mass spectrometer’s
settings were, full MS scan range 350 to 1500 m/z, with
mass resolution of 60,000 at 400 m/z, 50 μs scan time
with accumulation of three microscans. The three most
intense ions from this full MS scan were fragmented indata-dependent manner with CID, using an exclusion
list of 500 ions during 30 seconds. Triplicate NanoLC-MS
analyses were run for every venom digest sample.
Protein Identification
Analysis of mass spectrometric data was performed using
three different search engines: Mascot (version 2.4),
Proteome Discoverer (version 1.2) and PEAKS (version 4.2
SP 1). Fragmentation spectra were filtered using Proteome
Discoverer, allowing only double to quadruply charged
ions, and removing the precursor ion within a window of
1 Da. Processed spectra were searched using Sequest and
Mascot. Two missed cleavages were allowed, and precursor
and fragment mass tolerance were set to 20 ppm and
0.8 Da, respectively. Carboxyamidomethylation of cysteine
was set as a fixed modification, while methionine oxidation
and asparagine and glutamine deamidation were set
as variable modifications. Enzymes used for sequencing
(trypsin, R and K; chymotrypsin, F, L,W, and Y; Glu-C, D
and E) were specified in each case. For naturally occurring
peptides (undigested venom samples), no enzyme was
specified in the search. A constructed database, using
the six possible frames for each detected transcript, with
the common Repository of Adventitious Proteins – cRAP
(http://www.thegpm.org/crap/) was used for both search
algorithms (Protobothrops plus cRAP = 20,945 entries;
Ovophis plus cRAP = 15,264 entries). Protein and peptide
identifications from Mascot and Sequest results were
combined, setting the false discovery rate to 1%.
Spectra not identified were submitted for de-novo se-
quencing using PEAKS. Search parameters were the same
as defined for Mascot and Sequest, except for specifying
the mass spectrometer as an FT-trap, and allowing ≤3
modifications per peptide. Results were filtered to allow
only sequences with rank equal to zero and a PEAKS
score higher than 20. These sequences were BLASTed
against our constructed databases, and filtered, allowing
only matches with an E score <0.05.
Combined results of all three search engines were used to
report protein and peptide identifications. The same search
(using Mascot and Sequest only) was performed using
the NCBI database, subset for snake taxonomy (txid8570;
40,887 sequences).
RNA-seq and proteomic comparisons
Because longer transcripts produce more fragments,
RNA-seq data are typically analyzed using metrics which
standardize the number of reads mapped to a particular
exon by the total number of mapped reads and the size of
the exon [210]. We attempted an analogous measure of
protein abundance based on peptides, to prevent longer
proteins from appearing more abundant than they are.
Unlike mRNA reads, each of which competes for a
position in the flow cell, with adequate chromatographic
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elution from the liquid chromatograph, and should be
detected independently of one another. Under this
assumption, we did not standardize by the total number
of detected fragments. For each protein identified, we
counted the total number of peptide fragments. Then
we divided this number by the length of the protein to
standardize for size, producing a measure of peptides per
unit length of protein, which could then be correlated
with the FPKM metric, computed as described above. The
count of each peptide mapping to different proteins was
divided by the number of matches, to account for
mapping uncertainty.
To evaluate the robustness of our analysis relative to the
reference protein data set chosen, a separate analysis was
conducted using snake venom proteins from the publicly
available NCBI database, for protein identification. This
analysis was conducted as described above, except that
that PEAKS identification was omitted in the interest of
time. We used reciprocal best BLAST as the criterion for
establishing homology between NCBI data and the de
novo sequenced transcriptomes. This was a conservative
choice, since many isoforms or closely related genes could
generally have just one NCBI best hit.
The cRAP protein database, which lists common con-
taminants, was used to determine abundance thresholds
for including predicted proteins. To determine this cutoff,
we bootstrapped the 99.9% confidence intervals around the
abundance scores for human contaminant proteins, which
were most likely introduced during sample preparation,
and which should be present at much lower concentrations
than target proteins. Proteins below this threshold were
filtered from the analysis.
Additional files
Additional file 1: Table S1. Abundance of individual toxin transcripts
in the Protobothrops flavoviridis transcriptome, as RNA Fragments/Kilobase
of Transcript Sequence/Million Base Pairs Sequenced (FPKM), arranged by
toxin class. Transcripts that were less abundant than contaminant levels
(e.g. human keratin) were not included in this table, even in cases in
which peptides corresponding to those transcripts were isolated.
Transcripts in blue are complete while those in yellow are incomplete. All
significant venom constituents were identified by mass spectrometry. The
number of amino acid residues and the percent coverage of the
predicted protein by sequenced peptides are also shown. The expected
protein length was determined from the transcript length minus
untranslated regions and the putative signal peptide, if any.
Additional file 2: Table S4. Protobothrops flavoviridis transcripts that
had negligible FPKMs. Incomplete transcripts are highlighted in yellow;
complete transcripts are shown in blue. Peptide coverage data are
presented for those transcripts with sequenced peptides. There is a high
degree of certainty associated with all sequences except those
highlighted in gray, although they may also be valid.
Additional file 3: Table S2. Abundance of individual toxin transcripts
in the Ovophis okinavensis transcriptome, as RNA Fragments/Kilobase of
Transcript Sequence/Million Base Pairs Sequenced (FPKM), arranged by
toxin class. Transcripts that were less abundant than contaminant levels(e.g. human keratin) were not included in this table, even in cases in
which peptides corresponding to those transcripts were isolated.
Transcripts in blue are complete while those in yellow are incomplete. All
significant venom constituents were identified by mass spectrometry. The
number of amino acid residues and the percent coverage of the predicted
protein by sequenced peptides are also shown. The expected protein length
was determined from the transcript length minus untranslated regions and
the putative signal peptide, if any. *In the Ovophis transcriptome, an
incomplete transcript for bradykinin-potentiating peptides and C-type
natriuretic peptides was isolated. A single peptide was sequenced by mass
spectrometry, but based upon a BLAST search, it originated in the missing
portion of our transcript; hence coverage is given as 0%.
Additional file 4: Table S5. Ovophis okinavensis transcripts that had
negligible FPKMs. Incomplete transcripts are highlighted in yellow;
complete transcripts are shown in blue. Peptide coverage data are
presented for those transcripts with sequenced peptides. There is a high
degree of certainty associated with all sequences except those
highlighted in gray, although they may also be valid. ***One peptide
(RPPGPPIPP) and two derivatives of the Ovophis BPP sequence were
sequenced by mass spectrometry. This sequence does not occur in our
truncated transcript, so no percent coverage is given; however, it is
nearly identical to a proposed BPP from the N-terminal end of a BPP-CNP
transcript from Gloydius blomhoffii (RPPGPPIPR) [78,81] and from Bothrops
jararaca venoms [80].
Additional file 5: Table S3. Abundance of venom protein transcripts
by toxin class in Protobothrops flavoviridis and Ovophis okinavensis
venoms. The different envenomation strategies employed by these two
pit vipers differ significantly, as illustrated especially by expression levels
of MPs, PLA2s, SPs, and CRISPS. Color fills indicate primary functions of
toxin classes; however, many venom components have direct or indirect
secondary and even tertiary functions. Yellow: Neurotoxic; Pink:
Hypotensive; Blue: Anticoagulant; Green: Digestive. Some toxin functions
are strategically counterintuitive. For example, thrombin-like SPs are
directly pro-coagulant, but by activating the prey fibrinolytic system, their
ultimate effect is anticoagulant.
Additional file 6: Table S6. Peptide coverage of non-venom-related
transcripts from the cDNA libraries of Protobothrops flavoviridis venom
glands. “Adjusted Counts” were used to discount peptides that matched
multiple proteins, so as to avoid spuriously high values. Adjusted counts
were used to create Figure 2 and Additional file 8: Figure S1.
Additional file 7: Table S7. Peptide coverage of non-venom-related
transcripts from the cDNA libraries of Ovophis okinavensis venom glands.
“Adjusted Counts” were used to discount peptides that matched multiple
proteins, so as to avoid spuriously high values. Adjusted counts were
used to create Figure 2 and Additional file 8: Figure S1.
Additional file 8: Figure S1. Correlation between abundances of
proteins predicted using NCBI data (black) and de novo assembled
reference sequence (grey). Homologies between the two protein sets
were determined using reciprocal best BLAST, so many of the proteins
detected in the de novo transcriptome were omitted in the comparison,
because they did either did not have homology to known snake
proteins, or this relationship could not be determined with certainty, e.g.,
in the case of multiple isoforms or closely related genes. Nonetheless, the
correlation coefficients were close between the two data sets, suggesting
that the measure of protein abundance was robust to the choice of
protein reference data set (Protobothrops: NCBI r = 0.52, p = 0.014, Trinity
r = 0.64, p = 2.2e-16; Ovophis: NCBI r = 0.64, p = 1.2e-4, Trinity r = 0.68,
p = 6.3e-10). Note that the correlation coefficients differ slightly with Figure 2,
since the analysis presented in Additional file 8: Figure S1 did not involve
assignment of unmapped proteins by PEAKS.
Additional file 9: Figure S2. Alignment of metalloproteases from the
Protobothrops flavoviridis transcriptome. These sequences assort into two
distinct groups, upper and lower. Members of the lower group display
significant similarities and align well. Members of the upper group, for the
most part, align poorly with one another, and essentially not at all with
the lower group. Both groups contain both P-II and P-III MPs. Given the
size of many MPs, some of these partial sequences probably represent
non-overlapping segments, despite attempts by the software to align them.
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Ovophis okinavensis transcriptome, showing the sequences of five P-II and
three P-III MPs.
Additional file 11: Figure S4. Alignment of 18 serine protease
sequences from the Protobothrops flavoviridis transcriptome. SP12 appears
to be an inactive plasminogen activator transcript, while SP11 is probably
a truncated member of the same subclass.
Additional file 12: Figure S5. Alignment of 26 Ovophis okinavensis
serine protease sequences. It is impossible to infer biological activities
from these transcripts; however, the Ovophis transcripts seem to fall into
three or four structural subclasses or groupings. SP15 and related
sequences with clusters of three acidic residues (positions 121-123) and
three aromatic residues (position 132-134) appear most similar to
thrombin-like enzymes. SP05 and 06 all display a high percentage of
aliphatic and aromatic residues (positions 116-140), but their biological
activity is not known. SP08 is apparently a thrombin-like enzyme. SP09 is
most similar, based on this fragment, to an SP from Protobothrops jerdonii
venom that has lost two of the three catalytic residues of active SPs.
Additional file 13: Figure S6. Alignment of all CTL transcripts from
both venoms with sequences of convulxin (Crotalus durissus terrificus) and
flavocetin (Protobothrops flavoviridis). Protobothrops venom contained
various Factor IX/X binding proteins that were absent in Ovophis venom.
Additional file 14: Figure S7. Alignment of known bradykinin-potentiating
peptides from various viperid venoms showing the great sequence
variability in this toxin class [78-83,191,211-222].
Additional file 15: Figure S8. Alignment of Protobothrops flavoviridis
[AB851922] and Ovophis okinavensis [AB848286] dipeptidyl peptidase IV
sequences with two isomers from Gloydius brevicaudus venom. The
former sequences each possess a leucine residue in position 268 that is
missing in the Gloydius sequences. They also have Gly-80 where Gloydius
has Glu, Ile-85/Val, Asn-113/Ser, Thr-170/Ala, Ser-215/Arg, Ala-395/Ser,
Arg-502/Ser, Gly-632/Asp, and Glu-680/Lys. The Protobothrops sequence
lacks asparagine-133, which is present in the other three. Each of the
Okinawan species has accumulated several point mutations: Protobothrops
(Phe-73, Val-248, Ser-272, Leu-304, Thr-324, Asp-485,) and Ovophis (Val-73,
Ile-144, Thr-176, Thr-220, Thr-396, Val-473, Glu-559, Asn-577).
Additional file 16: Figure S9. Alignment of a partial vespryn transcript
with vespryn sequences from elapid and crotalid venoms. The Protobothrops
vespryn [AB851949] is most closely related to that from Lachesis, which also
displays a four-residue gap from positions 25-28. Only three of the first 70
residues differ between these two toxins. The three crotalid vespryns are all
28-32 residues longer at the N-terminus than the two corresponding toxins
from Ophiophagus hannah and Pseudechis australis venoms [223].
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